JP2007525516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007525516A5 JP2007525516A5 JP2007500959A JP2007500959A JP2007525516A5 JP 2007525516 A5 JP2007525516 A5 JP 2007525516A5 JP 2007500959 A JP2007500959 A JP 2007500959A JP 2007500959 A JP2007500959 A JP 2007500959A JP 2007525516 A5 JP2007525516 A5 JP 2007525516A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- alkylene
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 19
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 8
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims 5
- -1 thiazolidinedione-yl Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical group 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 4
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- VJYBBKPKVPQHSX-UHFFFAOYSA-N 3-[4-[(4-methoxyphenyl)methoxy]phenyl]pent-4-ynoic acid Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(C(CC(O)=O)C#C)C=C1 VJYBBKPKVPQHSX-UHFFFAOYSA-N 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- JEXFYYALLIJTNH-GOSISDBHSA-N (2r)-3-[(2-methylpropan-2-yl)oxy]-3-oxo-2-[(4-phenylmethoxyphenyl)methyl]propanoic acid Chemical compound C1=CC(C[C@@H](C(=O)OC(C)(C)C)C(O)=O)=CC=C1OCC1=CC=CC=C1 JEXFYYALLIJTNH-GOSISDBHSA-N 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- RCECATFPGPUPHW-UHFFFAOYSA-N 2-(n-(4-benzamidophenyl)anilino)acetic acid Chemical compound C=1C=C(NC(=O)C=2C=CC=CC=2)C=CC=1N(CC(=O)O)C1=CC=CC=C1 RCECATFPGPUPHW-UHFFFAOYSA-N 0.000 claims 1
- CVBJWCJYJMMHGC-UHFFFAOYSA-N 2-[4-[2-[[5-(4-chlorophenyl)furan-2-carbonyl]amino]ethyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(C=2C=CC(Cl)=CC=2)O1 CVBJWCJYJMMHGC-UHFFFAOYSA-N 0.000 claims 1
- AQAMBIJONMEPPJ-UHFFFAOYSA-N 2-[[2-[3-(3,4-dihydro-2h-1,5-benzodioxepin-7-yl)-2-methyl-4-oxochromen-7-yl]oxyacetyl]amino]acetic acid Chemical compound O1CCCOC2=CC(C=3C(=O)C4=CC=C(OCC(=O)NCC(O)=O)C=C4OC=3C)=CC=C21 AQAMBIJONMEPPJ-UHFFFAOYSA-N 0.000 claims 1
- ITCRVQYXNASVEK-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(furan-2-carbonylamino)propanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(O)=O)NC(=O)C1=CC=CO1 ITCRVQYXNASVEK-UHFFFAOYSA-N 0.000 claims 1
- MIOAEEYDTLXLIO-UHFFFAOYSA-N 3-(4-chlorophenyl)-3-(furan-2-carbonylamino)propanoic acid Chemical compound C=1C=C(Cl)C=CC=1C(CC(=O)O)NC(=O)C1=CC=CO1 MIOAEEYDTLXLIO-UHFFFAOYSA-N 0.000 claims 1
- NSEKSGAGVILKPQ-UHFFFAOYSA-N 3-(4-phenylmethoxyphenyl)pent-4-enoic acid Chemical compound C1=CC(C(C=C)CC(=O)O)=CC=C1OCC1=CC=CC=C1 NSEKSGAGVILKPQ-UHFFFAOYSA-N 0.000 claims 1
- SAXJVFTTWMMNML-UHFFFAOYSA-N 3-[(4-chlorobenzoyl)amino]-3-[4-(dimethylamino)phenyl]propanoic acid Chemical compound C1=CC(N(C)C)=CC=C1C(CC(O)=O)NC(=O)C1=CC=C(Cl)C=C1 SAXJVFTTWMMNML-UHFFFAOYSA-N 0.000 claims 1
- QWQOJGSHENBCAF-UHFFFAOYSA-N 3-[2-[2-(3,4-dimethylphenoxy)ethylsulfanyl]benzimidazol-1-yl]propanoic acid Chemical compound C1=C(C)C(C)=CC=C1OCCSC1=NC2=CC=CC=C2N1CCC(O)=O QWQOJGSHENBCAF-UHFFFAOYSA-N 0.000 claims 1
- KVEYFKWVTVCKMX-UHFFFAOYSA-N 3-[3-[2-chloro-4-(trifluoromethyl)phenoxy]phenyl]propanoic acid Chemical compound OC(=O)CCC1=CC=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 KVEYFKWVTVCKMX-UHFFFAOYSA-N 0.000 claims 1
- PPJHTJXGKHYVCG-UHFFFAOYSA-N 3-[4-(4-bromophenyl)phenyl]-3-phenylsulfanylpropanoic acid Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(CC(=O)O)SC1=CC=CC=C1 PPJHTJXGKHYVCG-UHFFFAOYSA-N 0.000 claims 1
- DHQNEDXCTOTLHE-UHFFFAOYSA-N 3-[4-(4-bromophenyl)phenyl]-4-phenylbutanoic acid Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(CC(=O)O)CC1=CC=CC=C1 DHQNEDXCTOTLHE-UHFFFAOYSA-N 0.000 claims 1
- CJWSPUJYICTNJU-UHFFFAOYSA-N 3-[5-[2-chloro-6-fluoro-4-(trifluoromethyl)phenoxy]-2,4-dinitrophenyl]propanoic acid Chemical compound C1=C([N+]([O-])=O)C(CCC(=O)O)=CC(OC=2C(=CC(=CC=2F)C(F)(F)F)Cl)=C1[N+]([O-])=O CJWSPUJYICTNJU-UHFFFAOYSA-N 0.000 claims 1
- IGJHXBXWVKYBQR-UHFFFAOYSA-N 3-amino-3-[4-[(4-bromo-2-methyl-5-oxo-1-phenylpyrazol-3-yl)methoxy]-3-methoxyphenyl]propanoic acid Chemical compound COC1=CC(C(N)CC(O)=O)=CC=C1OCC(N1C)=C(Br)C(=O)N1C1=CC=CC=C1 IGJHXBXWVKYBQR-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- AANBGNWGPUCJNQ-UHFFFAOYSA-N BrC1=C(OCC(O)=O)C(OCC)=CC(C(=NN)C=2C=C(Cl)C(Cl)=CC=2)=C1 Chemical compound BrC1=C(OCC(O)=O)C(OCC)=CC(C(=NN)C=2C=C(Cl)C(Cl)=CC=2)=C1 AANBGNWGPUCJNQ-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010023379 Ketoacidosis Diseases 0.000 claims 1
- 208000007976 Ketosis Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- MLBYLEUJXUBIJJ-UHFFFAOYSA-N pent-4-ynoic acid Chemical compound OC(=O)CCC#C MLBYLEUJXUBIJJ-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54874104P | 2004-02-27 | 2004-02-27 | |
| US60/548,741 | 2004-02-27 | ||
| US60157904P | 2004-08-12 | 2004-08-12 | |
| US60/601,579 | 2004-08-12 | ||
| PCT/US2005/005815 WO2005086661A2 (en) | 2004-02-27 | 2005-02-24 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007525516A JP2007525516A (ja) | 2007-09-06 |
| JP2007525516A5 true JP2007525516A5 (https=) | 2008-03-27 |
| JP5299810B2 JP5299810B2 (ja) | 2013-09-25 |
Family
ID=34976072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500959A Expired - Fee Related JP5299810B2 (ja) | 2004-02-27 | 2005-02-24 | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7816367B2 (https=) |
| EP (1) | EP1737809B1 (https=) |
| JP (1) | JP5299810B2 (https=) |
| KR (1) | KR20070004769A (https=) |
| CN (1) | CN1946666A (https=) |
| AR (1) | AR048306A1 (https=) |
| AU (1) | AU2005220728B2 (https=) |
| BR (1) | BRPI0508098A (https=) |
| CA (1) | CA2558585C (https=) |
| CR (1) | CR8642A (https=) |
| EA (1) | EA011010B1 (https=) |
| EC (1) | ECSP066887A (https=) |
| ES (1) | ES2433466T3 (https=) |
| IL (1) | IL177717A0 (https=) |
| IS (1) | IS8542A (https=) |
| MA (1) | MA28466B1 (https=) |
| NO (1) | NO20064362L (https=) |
| TW (1) | TW200539854A (https=) |
| WO (1) | WO2005086661A2 (https=) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| JP5299810B2 (ja) * | 2004-02-27 | 2013-09-25 | アムジエン・インコーポレーテツド | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| JP4859665B2 (ja) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| KR20070107022A (ko) | 2005-01-07 | 2007-11-06 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| GB0505437D0 (en) * | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
| US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| JP4324221B2 (ja) | 2005-08-26 | 2009-09-02 | 株式会社医薬分子設計研究所 | Ｐｐａｒアゴニスト活性を有する誘導体 |
| WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| WO2007031791A1 (en) | 2005-09-16 | 2007-03-22 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| KR100968705B1 (ko) * | 2005-10-27 | 2010-07-06 | 주식회사유한양행 | 신규의 2-페닐피리미딘 유도체 및 그의 제조방법 |
| UA95613C2 (ru) * | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
| US20090176885A1 (en) * | 2006-02-02 | 2009-07-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CA2646430A1 (en) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
| TW200815377A (en) * | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| CA2662305C (en) * | 2006-09-07 | 2012-04-17 | Amgen Inc. | Heterocyclic gpr40 modulators |
| AU2007292816B2 (en) * | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| US7750048B2 (en) * | 2006-11-15 | 2010-07-06 | Janssen Pharmaceutica Nv | GPR40 agonists |
| TW200838526A (en) | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
| JP5175866B2 (ja) * | 2007-02-22 | 2013-04-03 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇタンパク質共役受容体を調節するための化合物および方法 |
| EP2139843B1 (en) * | 2007-04-16 | 2013-12-25 | Amgen, Inc | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| CN102083783A (zh) * | 2007-10-10 | 2011-06-01 | 安姆根有限公司 | 取代的联苯gpr40调节剂 |
| US8299296B2 (en) * | 2007-10-26 | 2012-10-30 | Japan Tobacco Inc. | Spiro compounds and pharmaceutical use thereof |
| WO2009055932A1 (en) * | 2007-11-02 | 2009-05-07 | Prometic Biosciences Inc. | Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis |
| KR20100098653A (ko) * | 2007-11-21 | 2010-09-08 | 디코드 제네틱스 이에이치에프 | 염증의 치료를 위한 바이아릴 ｐｄｅ４ 억제제 |
| WO2009111056A1 (en) * | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| EP2272817A4 (en) * | 2008-04-11 | 2011-12-14 | Inst Med Molecular Design Inc | PAI-1 INHIBITORS |
| US8633245B2 (en) * | 2008-04-11 | 2014-01-21 | Institute Of Medicinal Molecular Design, Inc. | PAI-1 inhibitor |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| US8586607B2 (en) | 2008-07-28 | 2013-11-19 | Syddansk Universitet | Compounds for the treatment of metabolic diseases |
| AU2009303475B2 (en) * | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| NZ592603A (en) * | 2008-10-21 | 2013-02-22 | Metabolex Inc | Aryl gpr120 receptor agonists and uses thereof |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| JP2012136438A (ja) * | 2009-04-22 | 2012-07-19 | Astellas Pharma Inc | テトラゾール化合物 |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| DE102009046115A1 (de) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
| JPWO2011052756A1 (ja) | 2009-10-30 | 2013-03-21 | 持田製薬株式会社 | 新規３−ヒドロキシ−５−アリールイソキサゾール誘導体 |
| AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
| EP2332427A1 (en) | 2009-12-07 | 2011-06-15 | Nestec S.A. | low caloric fat replacers |
| NZ601408A (en) | 2009-12-25 | 2013-12-20 | Mochida Pharm Co Ltd | Novel 3-hydroxy-5-arylisothiazole derivative |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| US8530413B2 (en) * | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) * | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) * | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
| WO2012076466A2 (de) | 2010-12-07 | 2012-06-14 | Bayer Pharma Aktiengesellschaft | Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| HK1207853A1 (en) | 2011-04-08 | 2016-02-12 | 卡尔丹治疗有限公司 | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| BR112013027883A2 (pt) | 2011-04-27 | 2017-08-08 | Mochida Pharm Co Ltd | novo derivado de 1-óxido de 3-hidroxiisotiazol |
| AU2012248627A1 (en) | 2011-04-28 | 2013-11-14 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| TWI537262B (zh) * | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 |
| WO2013057743A1 (en) * | 2011-10-21 | 2013-04-25 | Connexios Life Sciences Pvt. Ltd | Process for the preparation of an aryl oxime and salts thereof |
| EP2800736A1 (en) * | 2012-01-04 | 2014-11-12 | Sanofi | 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, process for preparation thereof and use thereof as a medicament |
| NZ631569A (en) | 2012-02-28 | 2016-10-28 | Piramal Entpr Ltd | Phenyl alkanoic acid derivatives as gpr agonists |
| DE102012208530A1 (de) | 2012-05-22 | 2013-11-28 | Bayer Pharma AG | Substituierte Piperidinoacetamide und ihre Verwendung |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
| WO2014078610A1 (en) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Dihydropyrazole gpr40 modulators |
| WO2014086704A1 (en) | 2012-12-03 | 2014-06-12 | F. Hoffmann-La Roche Ag | Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1) |
| DE102013201104A1 (de) * | 2013-01-24 | 2014-07-24 | H.C. Starck Gmbh | Verfahren zur Herstellung von Chromnitrid-haltigen Spritzpulvern |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| EP2963027B1 (en) * | 2013-02-28 | 2018-12-26 | TiumBio Co., Ltd. | Tricyclic compound and use thereof |
| CN104109115B (zh) * | 2013-04-16 | 2016-11-23 | 中国科学院上海药物研究所 | 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途 |
| AR096041A1 (es) | 2013-04-17 | 2015-12-02 | Piramal Entpr Ltd | Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg |
| KR101569522B1 (ko) * | 2013-04-18 | 2015-11-17 | 현대약품 주식회사 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| WO2015000412A1 (zh) * | 2013-07-02 | 2015-01-08 | 四川海思科制药有限公司 | 苯并环丁烯类衍生物、其制备方法及其在医药上的应用 |
| CN104418801B (zh) * | 2013-08-19 | 2016-10-05 | 上海润诺生物科技有限公司 | 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| IN2013MU03577A (https=) | 2013-11-14 | 2015-07-31 | Cadila Healthcare Ltd | |
| ES2747973T3 (es) | 2013-11-15 | 2020-03-12 | Merck Sharp & Dohme | Compuestos tricíclicos antidiabéticos |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| TW201609722A (zh) | 2013-12-13 | 2016-03-16 | 美國禮來大藥廠 | 新穎三唑并吡啶化合物 |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| KR20160095117A (ko) * | 2014-01-10 | 2016-08-10 | 일라이 릴리 앤드 캄파니 | 페닐-트리아졸로-피리딘 화합물 |
| US9809592B2 (en) | 2014-01-10 | 2017-11-07 | Eli Lilly And Company | Isopropyl triazolo pyridine compounds |
| EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| AU2015220427B2 (en) | 2014-02-19 | 2017-09-21 | Piramal Enterprises Limited | Compounds for use as GPR120 agonists |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2016012965A2 (en) | 2014-07-25 | 2016-01-28 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof |
| US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| WO2016038540A1 (en) | 2014-09-11 | 2016-03-17 | Piramal Enterprises Limited | Fused heterocyclic compounds as gpr120 agonists |
| TW201629033A (zh) | 2014-10-08 | 2016-08-16 | 健生藥品公司 | 作為治療第二型糖尿病之ｇｐｒ４０促效劑的經取代苯并噻吩基衍生物 |
| WO2016060517A2 (ko) * | 2014-10-17 | 2016-04-21 | 현대약품 주식회사 | 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제 |
| KR20170098869A (ko) | 2014-12-18 | 2017-08-30 | 바이엘 파마 악티엔게젤샤프트 | 치환된 피리딜-시클로알킬-카르복실산, 그를 함유하는 조성물 및 그의 의학적 용도 |
| US9908873B2 (en) | 2015-08-12 | 2018-03-06 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
| WO2017027312A1 (en) | 2015-08-12 | 2017-02-16 | Janssen Pharmaceutica Nv | Gpr40 agonists for the treatment of type ii diabetes |
| US9920040B2 (en) | 2015-08-12 | 2018-03-20 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
| CN105198826A (zh) * | 2015-10-08 | 2015-12-30 | 中国药科大学 | 3,5-二甲基异噁唑类衍生物、其制备方法及其作为药物的用途 |
| WO2017172505A1 (en) | 2016-03-29 | 2017-10-05 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10106553B2 (en) | 2016-04-11 | 2018-10-23 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
| WO2017180457A1 (en) | 2016-04-11 | 2017-10-19 | Janssen Pharmaceutica Nv | Gpr40 agonists in anti-diabetic drug combinations |
| CU24576B1 (es) | 2016-05-04 | 2022-02-04 | Centro De Investig Y Desarrollo De Medicamentos Cidem | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| KR102007633B1 (ko) | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| CN109666027A (zh) * | 2017-10-17 | 2019-04-23 | 中国科学院上海药物研究所 | 一类酰胺结构的gpr40激动剂化合物及其用途 |
| EP3709995A4 (en) | 2017-11-16 | 2021-04-14 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US11964938B2 (en) * | 2018-01-08 | 2024-04-23 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists |
| CN110092774B (zh) * | 2018-01-29 | 2022-04-08 | 中国科学院上海药物研究所 | 芳香丙酸类衍生物、及其制备方法和用途 |
| US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
| US12338206B2 (en) | 2019-02-21 | 2025-06-24 | Nanjing Ruijie Pharma Co., Ltd. | Compounds and their uses as thyroid hormone receptor agonists |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| AU2021225966A1 (en) * | 2020-02-28 | 2022-09-15 | Kallyope, Inc. | GPR40 agonists |
| WO2022269439A1 (en) * | 2021-06-21 | 2022-12-29 | Ildong Pharmaceutical Co., Ltd. | Method of controlling blood sugar level and treatment of diabetes and related conditions |
| WO2023080299A1 (ko) * | 2021-11-08 | 2023-05-11 | 일동제약(주) | 페닐 프로피온 산 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| CN116924906A (zh) * | 2022-03-31 | 2023-10-24 | 广东药科大学 | 一种新型长效ffa1激动剂、其制备方法及其作为药物的用途 |
| JP2025110317A (ja) * | 2024-01-15 | 2025-07-28 | 信越化学工業株式会社 | 有機膜形成用組成物、有機膜形成方法、及びパターン形成方法 |
| KR20250173452A (ko) * | 2024-06-03 | 2025-12-10 | 현대약품 주식회사 | 당뇨병의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE305216B (https=) * | 1965-09-17 | 1968-10-21 | Astra Apotekarnes Kem Fab | |
| FR2359135A1 (fr) | 1976-07-22 | 1978-02-17 | Hexachimie | Nouvelles phenoxyhydroxypropylamines, procede pour les preparer et leur application en therapeutique |
| US4760089A (en) * | 1985-09-09 | 1988-07-26 | Smithkline Beckman Corporation | Irreversible dopamine-β-hydroxylase inhibitors |
| PT85081A (en) | 1986-06-19 | 1987-07-01 | Smithkline Beckman Corp | Irreversible dopamine-beta-hydroxylase inhibitors |
| GB8917069D0 (en) | 1989-07-26 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| CA2135173A1 (en) | 1992-05-20 | 1993-11-25 | Bruce E. Witzel | Ester derivatives of 4-aza-steroids |
| EP0641204B1 (en) | 1992-05-20 | 2000-08-16 | Merck & Co. Inc. | 17-ethers and thioethers of 4-aza-steroids |
| DE4241632A1 (de) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| JP3894949B2 (ja) | 1993-06-30 | 2007-03-22 | ザ、ウェルカム、ファンデーション、リミテッド | 抗アテローム性動脈硬化症ジアリール化合物 |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| AU4432496A (en) * | 1994-12-23 | 1996-07-19 | Dr. Karl Thomae Gmbh | Piperazine derivatives, medicaments containing the same, their use and process for preparing the same |
| US6037367A (en) * | 1995-07-14 | 2000-03-14 | Smithkline Beecham Corporation | Substituted-pent-4-ynoic acids |
| ATE259227T1 (de) | 1995-09-18 | 2004-02-15 | Ligand Pharm Inc | Behandlung von niddm (nichtinsulinabhängige diabetes mellitus) mit rxr agonisten |
| US5795900A (en) | 1995-10-03 | 1998-08-18 | Abbott Laboratories | Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis |
| CA2233888A1 (en) | 1995-10-06 | 1997-04-10 | Ligand Pharmaceuticals Incorporated | Dimer-selective rxr modulators and methods for their use |
| US5771109A (en) * | 1996-05-17 | 1998-06-23 | Pixar | Method and apparatus for digitizing films using a stroboscopic scanning system |
| JPH10316641A (ja) | 1997-03-14 | 1998-12-02 | Sankyo Co Ltd | カルボン酸誘導体 |
| WO1999011255A1 (en) | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
| US6645939B1 (en) * | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| WO1999030709A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
| DE19941567A1 (de) | 1998-09-05 | 2000-04-20 | Merck Patent Gmbh | Neue flüssigkristalline Verbindungen |
| EP1153017B1 (en) * | 1999-02-16 | 2006-05-03 | Aventis Pharma Limited | Bicyclic compounds and their use as integrin receptor ligands |
| WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| EP1177176B1 (en) | 1999-04-28 | 2006-04-19 | Aventis Pharma Deutschland GmbH | Tri-aryl acid derivatives as ppar receptor ligands |
| ATE263162T1 (de) | 1999-05-05 | 2004-04-15 | Aventis Pharma Ltd | Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren |
| US6262118B1 (en) | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| JP2001242165A (ja) | 2000-02-25 | 2001-09-07 | Dai Ichi Seiyaku Co Ltd | 採血用試薬 |
| JP2002003368A (ja) | 2000-06-23 | 2002-01-09 | Saitama Daiichi Seiyaku Kk | 経皮吸収又は経粘膜吸収用の製剤 |
| GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031527D0 (en) | 2000-12-22 | 2001-02-07 | Smithkline Beecham Plc | New use |
| CA2433573A1 (en) | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Alkanoic acid derivatives, process for their production and use thereof |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| EA200400011A1 (ru) | 2001-06-07 | 2004-06-24 | Эли Лилли Энд Компани | Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar) |
| US7345068B2 (en) * | 2002-02-07 | 2008-03-18 | Hitoshi Endou | Aromatic amino acid derivatives and medicinal compositions |
| WO2003068959A1 (fr) | 2002-02-14 | 2003-08-21 | Takeda Chemical Industries, Ltd. | Nouveau procede de criblage |
| US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| EP1513817A1 (en) | 2002-05-24 | 2005-03-16 | Takeda Pharmaceutical Company Limited | 1, 2-azole derivatives with hypoglycemic and hypolipidemic activity |
| GB0214149D0 (en) * | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| EP2662211A1 (en) | 2002-06-24 | 2013-11-13 | Tufts University | Silk biomaterials and methods of use thereof |
| AU2003261935A1 (en) | 2002-09-06 | 2004-03-29 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
| AU2003277576A1 (en) * | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| CA2521175A1 (en) | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| AU2004309271A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| EP1698624B1 (en) | 2003-12-26 | 2012-06-27 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
| JP5299810B2 (ja) * | 2004-02-27 | 2013-09-25 | アムジエン・インコーポレーテツド | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 |
| US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| JP4859665B2 (ja) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| JP2007269630A (ja) | 2004-06-23 | 2007-10-18 | Toudai Tlo Ltd | インスリン分泌促進剤 |
| US20060003344A1 (en) * | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
| JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
| EP1843766A1 (en) | 2005-01-28 | 2007-10-17 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| CA2593858A1 (en) | 2005-01-31 | 2006-08-10 | Min Ge | Antidiabetic bicyclic compounds |
| US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| CA2662305C (en) * | 2006-09-07 | 2012-04-17 | Amgen Inc. | Heterocyclic gpr40 modulators |
-
2005
- 2005-02-24 JP JP2007500959A patent/JP5299810B2/ja not_active Expired - Fee Related
- 2005-02-24 AU AU2005220728A patent/AU2005220728B2/en not_active Ceased
- 2005-02-24 EA EA200601388A patent/EA011010B1/ru not_active IP Right Cessation
- 2005-02-24 CN CNA2005800127092A patent/CN1946666A/zh active Pending
- 2005-02-24 ES ES05723623T patent/ES2433466T3/es not_active Expired - Lifetime
- 2005-02-24 WO PCT/US2005/005815 patent/WO2005086661A2/en not_active Ceased
- 2005-02-24 EP EP05723623.4A patent/EP1737809B1/en not_active Expired - Lifetime
- 2005-02-24 US US10/591,214 patent/US7816367B2/en active Active
- 2005-02-24 BR BRPI0508098-3A patent/BRPI0508098A/pt not_active IP Right Cessation
- 2005-02-24 CA CA2558585A patent/CA2558585C/en not_active Expired - Fee Related
- 2005-02-24 KR KR1020067019713A patent/KR20070004769A/ko not_active Withdrawn
- 2005-02-25 US US11/067,377 patent/US7649110B2/en active Active
- 2005-02-28 AR ARP050100748A patent/AR048306A1/es unknown
- 2005-03-01 TW TW094106166A patent/TW200539854A/zh unknown
-
2006
- 2006-08-27 IL IL177717A patent/IL177717A0/en unknown
- 2006-09-13 MA MA29319A patent/MA28466B1/fr unknown
- 2006-09-20 CR CR8642A patent/CR8642A/es not_active Application Discontinuation
- 2006-09-26 NO NO20064362A patent/NO20064362L/no not_active Application Discontinuation
- 2006-09-27 EC EC2006006887A patent/ECSP066887A/es unknown
- 2006-09-27 IS IS8542A patent/IS8542A/is unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007525516A5 (https=) | ||
| CA2558585A1 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
| JP2009507846A5 (https=) | ||
| DK2799427T3 (en) | Therapeutic compounds | |
| JP2010530438A5 (https=) | ||
| JP2005514334A5 (https=) | ||
| CA2435067A1 (en) | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | |
| JP2014502979A5 (https=) | ||
| JP2007500720A5 (https=) | ||
| CA2662305A1 (en) | Heterocyclic gpr40 modulators | |
| AU2007292816A1 (en) | Benzo-fused compounds for use in treating metabolic disorders | |
| JP2016503786A5 (https=) | ||
| RU2006126978A (ru) | Производные 3-(4-бензилоксифенил)пропановой кислоты | |
| JP2007502264A5 (https=) | ||
| EP1975149A1 (en) | 1,3-bis(substituted phenyl)-3-hydroxypropan-1-one or 2-propen-1-one compound, and salt thereof | |
| JP2012512178A5 (https=) | ||
| JP2016512844A5 (https=) | ||
| WO2010027051A1 (ja) | 置換アセトフェノン化合物、その製造方法及び用途 | |
| RU2746602C2 (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
| WO2009151695A4 (en) | Compounds and method for reducing uric acid | |
| RU2019111882A (ru) | Антагонисты trpv4 | |
| RU2009148304A (ru) | Модуляторы гидролазы амидов жирных кислот на основе гетероарилзамещенной мочевины | |
| JP2017507915A5 (https=) | ||
| RU2011104223A (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| EA025199B1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии |